Tardive dyskinesia and essential fatty acids (Q36508056)

14 August 2017

1 reference

title

Tardive dyskinesia and essential fatty acids (English)

1 reference

14 August 2017

0 references

1 reference

Krishna Vaddadi

1

1 reference

14 August 2017

Kerstin Hakansson

series ordinal

2

1 reference

14 August 2017

Jerry Clifford

series ordinal

3

1 reference

14 August 2017

John Waddington

series ordinal

4

1 reference

14 August 2017

publication date

1 April 2006

1 reference

International Review of Psychiatry

14 August 2017

published in

1 reference

14 August 2017

volume

18

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

133-143

1 reference

Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Association of diabetes with dyskinesia in older psychosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Oxidative stress, glutamate, and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acids in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarboxylase messenger RNA in the reticular thalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Tardive dyskinesia. A discontinuation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The importance of free radicals and catalytic metal ions in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Reactive oxygen species and protein oxidation in aging: a look back, a look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Fatty acid levels in the brains of schizophrenics and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

omega-3 Fatty acid for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The membrane hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Prostaglandin E1 in normal human skin: methodological evaluation, topographical distribution and data related to sex and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Antipsychotic drugs differentially modulate apolipoprotein D in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Oxidative stress during treatment with first- and second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The effects of clozapine on tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Oxygen radicals and neuropsychiatric illness. Some speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Oxidative mechanisms and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Oxidative injury and potential use of antioxidants in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Possible association between tardive dyskinesia and altered carbohydrate metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Metabolic risk during antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Tardive dyskinesia in psychiatric patients with substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Pharmacology of cannabinoid CB1 and CB2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The endocannabinoid system as a target for therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Haloperidol- and clozapine-induced oxidative stress in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Rate of tardive dyskinesia in hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Ageing and the free radical theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

The desaturation step in the animal biosynthesis of polyunsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Increased tardive dyskinesia in alcohol-abusing schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

An experimental model of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Positive and negative subtypes in acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Orofacial dyskinesia and the alcohol dependence syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Schizophrenic symptoms and dietary intake of n-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Sustained Remission of Positive and Negative Symptoms of Schizophrenia Following Treatment With Eicosapentaenoic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Schizophrenia, tardive dyskinesia and essential fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Essential fatty acid supplementation in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540260600583114

10.1080/09540260600583114

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference